Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
Immunovant(IMVT) Zacks Investment Research·2024-04-22 16:56Immunovant, Inc. (IMVT) is a New York-based biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. The company currently has no marketed products in its commercial portfolio.Immunovant’s clinical-stage pipeline comprises its lead product candidate, batoclimab (formerly known as IMVT-1401), and a new candidate, IMVT-1402, which are being developed as a subcutaneous injection for the treatment of IgG-mediated autoimmune diseases.Let’s delve deeper to discuss ...